Multihance

Active Ingredient:: Gadobenate Dimeglumine
Origin:: EU

Multihance (Gadobenate Dimeglumine)

Q: What is Multihance used for?

Multihance is an injectable gadolinium‑based contrast agent used to enhance magnetic resonance imaging of the central nervous system, liver, cardiovascular system and for MR angiography. It improves the visibility of anatomical structures and pathological lesions during MRI examinations.

Q: How does gadobenate dimeglumine work?

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. When administered intravenously, it distributes in the extracellular space and increases signal intensity on T1‑weighted MRI, providing clearer differentiation between normal and abnormal tissues.

Q: What is the usual dose of Multihance?

The dose of Multihance is determined by the prescribing physician based on the specific imaging protocol, patient weight, and renal function. The healthcare professional calculates the appropriate volume to achieve optimal contrast enhancement for the intended MRI study.

Q: Is Multihance safe during pregnancy or breastfeeding?

Multihance is classified as Pregnancy Category C, meaning it should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; therefore, clinicians should consider the benefits and possible exposure to the infant before administration.

Q: How do I order Multihance from GNH India?

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Q: How does Multihance compare with other MRI contrast agents?

Compared with other gadolinium‑based agents, gadobenate dimeglumine offers higher relaxivity, which can provide stronger signal enhancement at lower doses. This may improve image quality, especially in liver and cardiovascular imaging, while maintaining a safety profile similar to other macrocyclic gadolinium agents.

Q: What are the storage and handling requirements for Multihance?

Multihance should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Q: How is Multihance administered?

Multihance is administered as an intravenous injection, typically through a peripheral or central line. The injection is given as a bolus or slow infusion, depending on the imaging protocol, and is performed by qualified healthcare personnel under aseptic conditions.

Q: What are the most serious risks associated with Multihance?

The most serious risks include allergic reactions such as anaphylaxis and nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment. Prompt recognition and management of these reactions are essential, and the drug should be avoided in patients with known severe kidney dysfunction.

Q: Who should not receive Multihance?

Multihance should not be used in patients with a history of severe allergic reaction to gadolinium‑based agents, those with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of NSF, and in pregnant women unless clearly indicated. Clinicians should assess each patient individually.

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It enhances magnetic resonance imaging of specific organs and vascular structures in patients undergoing diagnostic examinations.

GNH India supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bracco Imaging S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Multihance is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging of several organ systems.

Central nervous system: enhances visualization of brain and spinal cord structures during MRI.
Liver: provides high‑contrast images of hepatic tissue and lesions.
Cardiovascular system and angiography: improves delineation of blood vessels and cardiac anatomy in MRI studies.

How It Works

Gadobenate dimeglumine is a paramagnetic gadolinium chelate that shortens T1 relaxation time of nearby water protons. After intravenous injection it distributes in the extracellular fluid and rapidly enters tissues, where its magnetic properties increase signal intensity on T1‑weighted MRI, thereby improving the contrast between normal and pathological structures.

Side Effects

Multihance may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

Nausea: mild, usually resolves without intervention.
Headache: transient discomfort after injection.
Injection site discomfort: mild pain or burning sensation.
Warmth sensation: feeling of heat in the body during administration.
Dizziness: brief episodes of light‑headedness.
Metallic taste: temporary alteration of taste.

Serious or Rare Side Effects

Allergic reaction or anaphylaxis: severe hypersensitivity requiring immediate medical attention.
Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment.
Severe hypotension: sudden drop in blood pressure.
Arrhythmia: irregular heart rhythm.
Pulmonary edema: fluid accumulation in the lungs.
Severe skin rash: extensive dermatologic reaction.

Precautions & Warnings

Prior to using Multihance, clinicians should assess patient‑specific risk factors and follow handling guidelines.

Renal function assessment: evaluate kidney function before administration, especially in patients with GFR <30 mL/min/1.73 m².
Pregnancy: use only if clearly needed, as it is classified as Category C.
Breastfeeding: consider potential exposure to the infant; weigh benefits against risks.
History of hypersensitivity: avoid or use with caution in patients with prior reactions to gadolinium agents.
Concurrent nephrotoxic drugs: monitor renal status closely when used with other nephrotoxic medications.
Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Multihance can interact with other agents that affect renal function or chelation processes.

Major Interactions (Avoid)

Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid use.
High‑dose iodinated contrast within 24 h: may compound renal toxicity.
Chelating agents (e.g., deferoxamine): may reduce the efficacy of gadolinium binding.

Moderate Interactions (Monitor Closely)

Loop diuretics: may alter renal clearance of the contrast.
Nephrotoxic antibiotics (e.g., aminoglycosides): monitor kidney function during concurrent therapy.

Frequently Asked Questions

Multihance is an injectable gadolinium‑based contrast agent used to enhance magnetic resonance imaging of the central nervous system, liver, cardiovascular system and for MR angiography. It improves the visibility of anatomical structures and pathological lesions during MRI examinations.

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. When administered intravenously, it distributes in the extracellular space and increases signal intensity on T1‑weighted MRI, providing clearer differentiation between normal and abnormal tissues.

The dose of Multihance is determined by the prescribing physician based on the specific imaging protocol, patient weight, and renal function. The healthcare professional calculates the appropriate volume to achieve optimal contrast enhancement for the intended MRI study.

Multihance is classified as Pregnancy Category C, meaning it should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; therefore, clinicians should consider the benefits and possible exposure to the infant before administration.

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other gadolinium‑based agents, gadobenate dimeglumine offers higher relaxivity, which can provide stronger signal enhancement at lower doses. This may improve image quality, especially in liver and cardiovascular imaging, while maintaining a safety profile similar to other macrocyclic gadolinium agents.

Multihance should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Multihance is administered as an intravenous injection, typically through a peripheral or central line. The injection is given as a bolus or slow infusion, depending on the imaging protocol, and is performed by qualified healthcare personnel under aseptic conditions.

The most serious risks include allergic reactions such as anaphylaxis and nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment. Prompt recognition and management of these reactions are essential, and the drug should be avoided in patients with known severe kidney dysfunction.

Multihance should not be used in patients with a history of severe allergic reaction to gadolinium‑based agents, those with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of NSF, and in pregnant women unless clearly indicated. Clinicians should assess each patient individually.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.